Investments, Funding & Disinvestment

The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.

The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.

Varipulse Pro will receive prominent visibility at the European Heart Rhythm Association (EHRA) annual meeting, where J&J plans to conduct live procedure demonstrations and offer practical training sessions for healthcare professionals.

Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners co-led the financing initiative.

The government has set a bold target: by 2030, Egypt will manufacture 140 million human vaccine doses per year.

Both nations will work together to strengthen their health information systems through coordinated collection, analysis, and sharing of epidemiological data, scientific research findings, and public health intelligence.

The Maisons-Alfort plant, which previously operated under Sanofi’s ownership, specializes in fill-finish manufacturing at commercial scale.

Jeito II will back between 15 and 20 clinical-stage biopharma companies, primarily in Europe, with average investments of up to €150 million (USD180 million) per company

Since launching in 2024, AI Airlock has grown steadily, moving beyond its initial pilot phase to tackle increasingly complex regulatory questions.

EverSea Medicines will make an initial payment of US$150 million at closing, followed by two additional payments of US$50 million each, scheduled for the first quarters of 2028 and 2029, subject to agreed conditions.